{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:37:11Z","timestamp":1790797031600,"version":"4.1.0"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00528","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:29:57Z","timestamp":1561508997000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice"],"prefix":"10.3389","volume":"9","author":[{"given":"Sara","family":"Galimberti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Genuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mazziotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ciabatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/annonc\/mdr058","article-title":"R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group","volume":"23","author":"Gang","year":"2012","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy(MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood.V92.3.784","article-title":"Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML\/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter \u201cAIDA\u201d trial. GIMEMA-AIEOP Multicenter \u201cAIDA\u201d Trial","volume":"92","author":"Diverio","year":"1998","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.critrevonc.2016.05.009","article-title":"Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: an emerging clinical question","volume":"103","author":"Sweet","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1038\/leu.2012.246","article-title":"EuroClonality\/BIOMED-2 guidelines for interpretation and reporting of Ig\/TCR clonality testing in suspected lymphoproliferations","volume":"26","author":"Langerak","year":"2012","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0889-8588(18)30232-6","article-title":"Role of autologous bone marrow transplantation in non-Hodgkin's lymphoma","volume":"7","author":"Vose","year":"1993","journal-title":"Hematol Oncol Clin North Am"},{"key":"B15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00001622-199409000-00005","article-title":"Management of follicular lymphoma","volume":"6","author":"Rohatiner","year":"1994","journal-title":"Curr Opin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/sj.bmt.1704102","article-title":"Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab","volume":"32","author":"Galimberti","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/bmt.2008.382","article-title":"Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma","volume":"43","author":"Hicks","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"B18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","author":"Corradini","year":"1997","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","article-title":"Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/asheducation-2016.1.437","article-title":"Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment","volume":"2016","author":"Hoster","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B22","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; Results from the nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.bbmt.2015.08.035","article-title":"Pre-transplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission","volume":"22","author":"Cowan","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/blood-2018-99-112655","article-title":"Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8 year follow up of CALGB 50403 (alliance)","volume":"132","author":"Kaplan","year":"2018","journal-title":"Blood."},{"key":"B27","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.2009.25.0852","article-title":"BCL-2\/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed\/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","article-title":"Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program","volume":"122","author":"Ladetto","year":"2013","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III First-LineIndolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/bjh.12695","article-title":"Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study","volume":"164","author":"Ibatici","year":"2014","journal-title":"Br J Haematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab vs. CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1182\/blood-2018-99-115930","article-title":"Minimal residual disease response at end of induction and during maintenance correlates with updated outcome in the phase III GALLIUM study of obinutuzumab- or rituximab-based immunochemotherapy in previously untreated follicular lymphoma patients","volume":"132","author":"Pott","year":"2018","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood.V128.22.613.613","article-title":"Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study","volume":"128","author":"Pott","year":"2016","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3389\/fphar.2017.00413","article-title":"The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: an Italian retrospective study","volume":"8","author":"Galimberti","year":"2017","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/blood-2018-99-114442","article-title":"Comprehensive minimal residual disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial for younger patients with mantle cell lymphoma: a kinetic model ensures a more refined risk stratification","volume":"132","author":"Ferrero","year":"2018","journal-title":"Blood."},{"key":"B40","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2013-09-526202","article-title":"Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK\u2013positive anaplastic large-cell lymphoma","volume":"123","author":"Damm-Welk","year":"2014","journal-title":"Blood."},{"key":"B41","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/j.1365-2141.2011.08681.x","article-title":"Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III\/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report","volume":"153","author":"Shiramizu","year":"2011","journal-title":"Br J Haematol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/bjh.13443","article-title":"Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report","volume":"170","author":"Shiramizu","year":"2015","journal-title":"Br J Haematol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1182\/blood-2018-99-114934","article-title":"CD19-CAR T cells treatment for minimal residual disease in B-cell lymphoma with a higher response rate and fewer adverse reactions","volume":"132","author":"Xiao","year":"2018","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1182\/blood-2018-99-111692","article-title":"Chemotherapy-free combination of obinutuzumab and ibrutinib in first LINE treatment of follicular lymphoma. The alternative study by the german low grade lymphoma study group (GLSG)","volume":"132","author":"Schmidt","year":"2018","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/epi-2018-0123","article-title":"Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance","volume":"11","author":"Feng","year":"2019","journal-title":"Epigenomics."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Non invasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/14737159.2017.1319765","article-title":"The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential","volume":"17","author":"Camus","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"B49","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/10428194.2018.1474463","article-title":"Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy","volume":"60","author":"Hossain","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B50","first-page":"1213","article-title":"Third complementarity determining region (CDR III) sequence analysis in childhood B-lineage acute lymphoblastic leukaemia: implications for the design of oligonucleotide probes for use in monitoring minimal residual disease","volume":"6","author":"Steward","year":"1992","journal-title":"Leukemia."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1038\/sj.leu.2401246","article-title":"Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes","volume":"12","author":"Pongers-Willemse","year":"1998","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S0145-2126(99)00110-1","article-title":"An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection","volume":"23","author":"Galimberti","year":"1999","journal-title":"Leuk Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/gcc.2870030206","article-title":"Structural alterations in the 5' region of the BCL2 gene in follicular lymphomas with BCL2-MBR or BCL2-MCR rearrangements","volume":"3","author":"Mikraki","year":"1991","journal-title":"Genes Chromosomes Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/sj.leu.2402568","article-title":"Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features: specific subtypes or same disease?","volume":"16","author":"Buchonnet","year":"2002","journal-title":"Leukemia"},{"key":"B55","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood.V83.7.1871.1871","article-title":"Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle celllymphomas","volume":"83","author":"Rimokh","year":"1994","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00019606-199808000-00005","article-title":"Molecular methods for detecting t(11;14) translocations in mantle-cell lymphomas","volume":"7","author":"Fan","year":"1998","journal-title":"Diagn Mol Pathol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/labmed\/lmw006","article-title":"Optimization and validation of an 8-color single-tube assay for the sensitive detection of minimal residual disease in B-cell chronic lymphocytic leukemia detected via flow cytometry","volume":"47","author":"Dowling","year":"2016","journal-title":"Lab Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"key":"B61","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparamteric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/jcp.56.2.129","article-title":"A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders","volume":"56","author":"Sah","year":"2003","journal-title":"J Clin Pathol"},{"key":"B64","first-page":"159","article-title":"Contribution of flow cytometric immunophenotyping and bone marrow trephine biopsy in the detection of lymphoid bone marrow infiltration in non-Hodgkin's lymphomas","volume":"51","author":"Mazur","year":"2004","journal-title":"Neoplasma"},{"key":"B65","first-page":"253","article-title":"Combination of morphology, flow cytometry and PCR assay to detect bone marrow infiltration in B-cell non-Hodgkin's lymphomas","volume":"161","author":"Carulli","year":"2010","journal-title":"Clin Ter"},{"key":"B66","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-1-4939-9151-8_8","article-title":"Flow cytometric MRD detection in selected mature B-cell malignancies","volume":"1956","author":"B\u00f6ttcher","year":"2019","journal-title":"Methods Mol Biol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.bjhh.2017.05.002","article-title":"Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasms","volume":"39","author":"Arlindo","year":"2017","journal-title":"Rev Bras Hematol Hemoter."},{"key":"B68","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjh.12839","article-title":"Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients","volume":"166","author":"Garnache Ottou","year":"2014","journal-title":"Br J Haematol."},{"key":"B69","first-page":"686","article-title":"The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis","volume":"32","author":"Okada","year":"1991","journal-title":"J Nucl Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.649.","article-title":"Prognostic value of baseline and interim total metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET\/CT in patients with follicular lymphoma","author":"Liang","year":"2019","journal-title":"Cancer Res Treat"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00259-018-4198-6","article-title":"Prognostic analysis of interim 18F-FDG PET\/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy","volume":"46","author":"Yuan","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/sj.leu.2401889","article-title":"Characterisation of BCL2-JH rearrangements in follicular lymphoma: PCR detection of 3' BCL2 breakpoints and evidence of a new cluster","volume":"14","author":"Buchonnet","year":"2000","journal-title":"Leukemia"},{"key":"B77","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-4939-9151-8_9","article-title":"MRD Detection in B-cell non-hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR","volume":"1956","author":"Pott","year":"2019","journal-title":"Methods Mol Biol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1365-2141.1999.01314.x","article-title":"Molecular analysis of bcl-1\/IgH junctional sequences in mantle cell lymphoma: potential mechanism of the t(11;14) chromosomal translocation","volume":"105","author":"Stamatopoulos","year":"1999","journal-title":"Br J Haematol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/00000478-198611000-00005","article-title":"Mantle zone lymphoma. Immuno- and enzyme histochemical studies on the cell of origin","volume":"10","author":"van den Oord","year":"1986","journal-title":"Am J Surg Pathol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-4939-3360-0_5","article-title":"Digital PCR: principles and applications","volume":"1392","author":"Kanagal-Shamanna","year":"2016","journal-title":"Methods Mol Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jmoldx.2015.05.007","article-title":"Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR","volume":"17","author":"Drandi","year":"2015","journal-title":"J Mol Diagn"},{"key":"B82","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/ijlh.12404","article-title":"Real-time PCR and droplet digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"37","author":"Fontanelli","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jmoldx.2017.01.004","article-title":"Droplet digital PCR is a reliable tool for monitoring minimal residual disease in acute promyelocytic leukemia","volume":"19","author":"Brunetti","year":"2017","journal-title":"J Mol Diagn"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1002\/cam4.2087","article-title":"Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation","volume":"8","author":"Bernardi","year":"2019","journal-title":"Cancer Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fphar.2016.00363","article-title":"The droplet digital PCR: a new valid molecular approach for the assessment of B-RAF V600E mutation in hairy cell leukemia","volume":"7","author":"Guerrini","year":"2016","journal-title":"Front Pharmacol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jmoldx.2018.03.002","article-title":"Droplet digital PCR is a robust tool for monitoring minimal residual disease in adult philadelphia-positive acute lymphoblastic leukemia","volume":"20","author":"Coccaro","year":"2018","journal-title":"J Mol Diagn"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3324\/haematol.2017.186528","article-title":"Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Drandi","year":"2018","journal-title":"Haematologica"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.3109\/10428194.2013.796053","article-title":"Next-generation sequencing of cancer consensus genes in lymphoma","volume":"54","author":"H\u00fcllein","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.3324\/haematol.2016.155424","article-title":"Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing","volume":"102","author":"Wren","year":"2017","journal-title":"Haematologica"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12859-017-1923-2","article-title":"HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data","volume":"18","author":"Beccuti","year":"2017","journal-title":"BMC Bioinformatics."},{"key":"B92","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1517\/14712598.2012.657622","article-title":"Obinutuzumab for the treatment of lymphoproliferative disorders","volume":"12","author":"Owen","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"B93","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-2-11","article-title":"ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature","volume":"2","author":"Brady","year":"2009","journal-title":"J Hematol Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.leukres.2007.01.002","article-title":"Quantitative PCR detection of NPM\/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma\u2014Residual disease monitoring and a correlation with the disease status","volume":"32","author":"Kalinova","year":"2008","journal-title":"Leukemia Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.16755.1","article-title":"Dissecting diffuse large B-cell lymphomas of the \u201cnot otherwise specified\u201d type: the impact of molecular techniques","volume":"7","author":"Pileri","year":"2018","journal-title":"F1000Res"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/annonc\/mdy450","article-title":"Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue","volume":"29","author":"Ciavarella","year":"2018","journal-title":"Ann Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1182\/blood-2018-99-116847","article-title":"Targeted next-generation sequencing of cell-free DNA in diffuse large B-cell lymphoma","volume":"132","author":"Zhang","year":"2018","journal-title":"Blood."},{"key":"B99","doi-asserted-by":"publisher","first-page":"5","DOI":"10.31487\/j.COR.2019.02.02","article-title":"Role of Circulating DNA in the Precocious Diagnosis of Lymphoma: an example in a Transplant-Related Aggressive Lymphoma","volume":"2","author":"Biavati","year":"2019","journal-title":"Clin Oncol Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.beha.2018.04.001","article-title":"CAR T cell therapy for B-cell lymphomas","volume":"31","author":"Chavez","year":"2018","journal-title":"Best Pract Res Clin Haematol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1182\/blood-2005-09-3634","article-title":"Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia","volume":"107","author":"Moreno","year":"2006","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.blre.2011.01.001","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies","volume":"25","author":"B\u00f6ttcher","year":"2011","journal-title":"Blood Rev."},{"key":"B103","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood.V114.22.202.202","article-title":"Flow cytometric detection of minimal residual disease one year post allogeneic stem cell transplantation predicts outcome in patients with B-CLL","volume":"114","author":"Oelschlaegel","year":"2009","journal-title":"Blood."},{"key":"B104","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/bmt.2016.305","article-title":"GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses","volume":"52","author":"Sellner","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1093\/annonc\/mdw419","article-title":"ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia","volume":"27","author":"Ladetto","year":"2016","journal-title":"Ann Oncol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/annonc\/mdx413","article-title":"ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma","volume":"29","author":"Buske","year":"2018","journal-title":"Ann Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00528\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,30]],"date-time":"2019-11-30T12:08:22Z","timestamp":1575115702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00528\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":107,"alternative-id":["10.3389\/fonc.2019.00528"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00528","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,26]]},"article-number":"528"}}